Healthcare company Imagion Biosystems has announced the success in achieving a key milestone of optimizing nanoparticle formulation in a drive to first-in-human testing.
In the announcement to ASX on 10 September 2018, the company has reported successful optimization of nanoparticle formulation in a test of IBX’s first intended clinical product. The test was targeted to detect the HER2 breast cancer cells in the lymph nodes.
This technical advancement has enabled the company to manufacture the first batch of the HER2 nanoparticle test reagent required to conduct toxicology study, thus moving closer to its first-in-human clinical study, expected to commence by early 2019.
During the remainder of 2018, nanoparticles are expected to be tested for safety and toxicity while the company intends to initiate the production of second batch of material for the initial human research study before the first-in-human study starts.
Imagion Biosystems’ stock is trading at $0.080 with no daily price change on 11 September 2018 (4:28 PM AEST).
The Income available from dividends remains attractive for many investors.
We take a look at the best yields on the market and assess what they say about a company’s prospect.
One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”
ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.
Click here to get your free report.
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.